Instaquit.org
Publisher DNA
What defines Instaquit.org?
AI intelligence is not yet available for Instaquit.org. The portfolio data below is up to date.
Portfolio
What does Instaquit.org ship?
Apps
1 app analysed
Human-in-the-loop coaching provides high-touch differentiation
- Psychological reframing of smoking habits effectively eliminates cravings without relying on willpower
- Opaque pricing structure hides costs behind a lengthy survey process before purchase
Distributed across 10 markets, strongest in Europe.
Based on 1 of 1 app with localized market data · last scanned .
Americas (3)
- Brazil1 / 1
- Mexico1 / 1
- United States1 / 1
Europe (5)
- France1 / 1
- Germany1 / 1
- Italy1 / 1
- Portugal1 / 1
- Spain1 / 1
Asia-Pacific (2)
- Japan1 / 1
- South Korea1 / 1
Core markets (1/1 apps)
User Sentiment
How do users feel about their apps?
1
Positive apps
0
Neutral / mixed
0
Negative apps
92/100
Avg sentiment score
Rivals
Who does Instaquit.org compete with?
The rivals identified
Nemeses(1)
Both apps target smokers seeking structured cessation support, with Smoke Free competing directly for the same user base through evidence-based cessation techniques and daily missions.
Contenders(10)
Both apps target users seeking to break substance dependency through behavioral modification and habit tracking, competing for the same health-conscious demographic.
Both apps compete for the same user base in the smoking cessation market by offering mobile-first behavioral tools to manage nicotine dependency.
Both apps target smokers seeking cessation tools, with QuitNow! capturing users through gamified milestone tracking while QuitSure focuses on psychological CBT-based reframing.
Both apps target the smoking cessation market, but Alive offers a gradual, tracker-based methodology that directly competes with the structured, CBT-focused 6-day program of QuitSure for users seeking lower-pressure alternatives.
Both apps target nicotine cessation, but quitSTART offers a free, government-backed alternative that directly challenges the subscription-gated model of QuitSure.
Both apps target nicotine cessation, competing for users seeking structured digital programs to quit smoking or vaping.
Both apps target nicotine cessation using cognitive behavioral therapy principles, competing for the same user base seeking non-willpower-reliant methods to quit smoking.
Both apps compete for the same audience of smokers and vapers, but they offer distinct methodologies: QuitSure uses a 6-day CBT-based program, while EasyQuit provides a self-guided, gamified experience for gradual reduction.
Both apps target nicotine cessation, but VapeFree focuses on gradual reduction via puff tracking and gamification, whereas QuitSure uses a structured CBT program.
Both apps target the smoking and vaping cessation market using behavior change strategies and human coaching, competing for the same user base seeking structured quit plans.
Same space(10)
Quitz applies similar behavioral science and motivational tasks to alcohol reduction instead of nicotine.
Exhale targets the same vaping cessation audience with a focus on daily accountability and health recovery tracking.
QuitBot uses a similar chatbot-led coaching model for smoking cessation but lacks active development.
QuitNow Smoking provides a clinical alternative to nicotine cessation by focusing on a 21-day transition period.
MindDay shares the CBT-based psychological approach to habit change but targets broader mental health rather than nicotine specifically.
CrushSmoke focuses on the same smoking cessation goal with a tracker-centric approach for monitoring progress and triggers.
Puff Count competes for the vaping cessation audience by using manual tracking and social accountability.
CraveMastery targets the same psychological craving management space but focuses on sugar rather than nicotine.
Escape the Vape offers a similar goal of vaping cessation but emphasizes community support and milestone tracking.
QuitWise expands the cessation scope to include both smoking and alcohol using a virtual pet gamification layer.